Updated Prognostic Factors in Localized NSCLC
Lung cancer is the most common cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) represents 80% of lung cancer subtypes. Patients with localized non-small cell lung cancer may be considered for upfront surgical treatment. However, the overall 5-year survival rate is 59%. To...
Main Authors: | Simon Garinet, Pascal Wang, Audrey Mansuet-Lupo, Ludovic Fournel, Marie Wislez, Hélène Blons |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/6/1400 |
Similar Items
-
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
by: Pengfei Zhao, et al.
Published: (2022-03-01) -
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
by: Zhang SS, et al.
Published: (2022-04-01) -
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
by: Arani Sathiyapalan, et al.
Published: (2023-10-01) -
Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database
by: Yan-qing Wang, et al.
Published: (2021-04-01) -
Primary Cervical Spinal Osteosarcoma Invading the Ligamentum Flavum: Case Report
by: Numan KARAARSLAN, et al.
Published: (2017-12-01)